Biodelivery sciences international, inc. (BDSI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total Revenues

38,278

31,637

30,306

29,677

19,769

18,028

14,156

12,175

11,281

-

11,253

8,744

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales

5,560

7,265

5,350

4,923

4,052

4,023

3,779

4,566

3,415

-

4,445

4,171

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product sales

-

-

-

-

-

-

-

-

-

-

-

-

7,795

-

2,009

2,110

2,102

1,492

1,155

833

677

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product royalty revenues

-

-

-

-

-

-

-

-

-

-

-

-

1,661

-

1,065

394

934

718

25

469

194

1,549

12

892

954

-

924

855

-

-

0

0

-

22

2,659

0

34

56

1,745

Research revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

0

0

14

-

-

33

-

-

-

Research and development reimbursements

-

-

-

-

-

-

-

-

-

-

-

-

22

-

497

0

4

-1

55

80

775

644

1,298

2,318

8,452

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

193

160

220

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

20,000

-

-

2,500

-

30,000

0

351

11,408

277

513

10,675

11,284

1,196

2,072

1,908

1,621

18,768

1,875

16,297

16,504

308

4

4

2

-

250

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

29,478

-

3,571

5,004

3,040

32,209

1,235

1,733

13,054

2,546

1,823

13,885

20,690

3,973

2,996

2,764

1,621

19,850

1,875

16,297

16,518

331

2,663

38

229

217

2,216

Cost of sales

-

-

-

-

-

-

-

-

-

-

-

-

5,645

-

2,314

4,094

2,550

2,657

1,699

2,621

1,124

3,063

463

687

726

373

643

690

375

785

375

375

375

378

1,507

-425

297

19

796

Expenses:
Research and development

-

-

0

-

-

863

699

854

2,484

6,753

1,986

1,590

2,671

5,091

4,402

4,008

5,377

5,096

4,473

4,506

6,549

4,909

6,770

7,983

14,623

12,149

16,387

12,758

12,032

11,560

12,546

6,546

4,711

3,179

6,215

4,720

6,690

3,215

1,521

Selling, general and administrative

26,736

23,759

23,360

21,955

16,989

17,587

13,489

14,021

13,505

14,773

14,867

15,970

13,259

11,740

12,054

12,496

13,055

13,502

14,715

13,287

13,181

-

13,648

7,256

-

-

-

3,110

2,910

-

2,992

2,209

2,840

1,318

2,593

1,930

1,764

2,092

2,196

Selling, general and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,628

-

3,049

-

-

-

-

-

-

-

-

-

-

-

-

Related party general and administrative, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

16

-

20

19

26

23

20

18

18

20

21

Impairment of intangible license

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

243

Total Expenses:

26,736

23,759

23,360

21,955

16,989

18,453

14,188

14,875

15,989

21,566

16,853

17,560

15,930

16,831

16,456

16,504

18,432

18,598

19,188

17,793

19,730

17,837

20,418

15,239

19,251

15,398

19,436

15,881

14,958

13,657

15,559

8,775

7,578

4,521

8,829

6,669

8,473

5,329

3,983

Income (loss) from operations

5,982

613

1,596

2,799

-1,272

-4,448

-3,811

-7,266

-8,123

-14,291

-10,045

-12,987

7,903

-15,200

-15,199

-15,594

-17,942

10,954

-19,652

-18,681

-7,800

-18,354

-19,058

-2,041

713

-11,799

-17,082

-13,808

-13,711

5,407

-14,058

7,147

8,564

-4,567

-7,672

-6,205

-8,541

-5,131

-2,563

Interest expense

1,293

1,308

1,234

13,937

2,561

2,595

2,567

2,525

2,505

1,920

1,893

1,878

2,886

789

786

914

778

786

785

527

420

-

515

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Bargain purchase gain

-

-

-

-

-

-

-

-

-

0

0

0

27,336

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-519

-555

-

-450

96

72

70

90

63

56

41

61

48

37

63

4

Derivative (loss) gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,685

-4,120

-4,825

-378

-917

392

1,024

3,277

-3,525

-3,478

-1,867

431

2,472

1,046

-487

-1,110

3,306

Other (expense) income, net

-1

-1

-3

8

0

-6

-2

1

-7

-

-13

-14

-

84

-6

-1

-13

3

-2

-3

27

-329

2

9

23

-55

-35

-95

-23

-30

16

50

-3

11

15

11

-27

10

28

Loss before income taxes

4,688

-696

359

-11,130

-3,833

-7,049

-6,380

-9,790

-10,635

-16,210

-11,951

-14,879

32,353

-15,942

-15,977

-16,486

-18,733

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income before taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18,486

-13,415

-12,637

8,725

-17,477

3,782

6,750

-

-

-

-

-

-

Income tax benefit (expense)

-278

-

5

-

0

-41

0

-20

74

0

0

0

-15,972

-

-

-

-

-

-

-

-

-

-

-

-

-

0

170

-85

-

0

0

-

-

-

-

-

-

-

Net (loss) income

-

-

354

-

-

-

-6,380

-

-

-16,210

-11,951

-14,879

48,325

-15,942

-15,977

-16,486

-18,733

10,171

-20,439

-19,211

-8,193

-

-25,256

-6,671

-

-

-

-

-

-

-17,477

3,782

6,750

-

-5,123

-5,098

-9,019

-6,168

775

Beneficial conversion feature of convertible preferred stock

-

-

0

-

-

-

12,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) attributable to common stockholders

4,966

-696

354

-11,130

-3,833

-7,008

-18,880

-9,770

-10,709

-

-11,951

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,644

-

-18,486

-13,415

-12,722

-

-

-

-

-

-5,123

-5,098

-

-6,168

775

Basic:
Basic and diluted:
Weighted average common stock shares outstanding, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

52,542

-

-

-

-

-

-

-

-

-

-

-

30,071

-

-

-

-

-

-

-0

-

Weighted average common stock shares outstanding, basic (in shares)

97,118

88,038

89,649

83,821

71,344

70,296

64,900

59,400

58,062

55,910

55,604

55,388

54,519

55,123

53,767

53,594

52,230

-

-

52,401

51,908

-

49,555

48,521

44,305

-

38,076

37,998

37,511

-

-

-

29,561

-

-

-

25,105

-

-

Basic and diluted loss per share

-

-

-

-0.13

-

-

-

-0.16

-0.18

-

-

-

-

-

-

-

-

-

-0.39

-0.37

-0.16

-

-0.51

-0.14

-

-

-

-

-0.34

-

-0.58

-

-

-

-

-

-

-

-

Basic earnings (loss) per share (in usd per share)

0.05

-

0.00

-

-0.05

-

-0.29

-

-

-0.31

-0.21

-0.27

0.89

-0.28

-0.30

-0.31

-0.36

-

-

-

-

-

-

-

-0.11

-

-0.49

-0.35

-

-

-

0.13

0.23

-0.11

-0.17

-0.18

-0.36

-

0.03

Diluted:
Weighted average common stock shares outstanding, diluted (in shares)

106,965

-

105,138

-

71,344

-

64,900

-

-

59,184

55,604

55,388

55,431

55,123

53,767

53,594

52,230

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29,586

-

-

-

25,105

-

-

Diluted earnings (loss) per share (in usd per share)

0.05

-

0.00

-

-0.05

-

-0.29

-

-

-0.30

-0.21

-0.27

0.87

-0.28

-0.30

-0.31

-0.36

-

-

-

-

-

-

-

-0.11

-

-0.49

-0.35

-

-

-

0.12

0.23

-0.11

-0.17

-0.18

-0.36

-

0.01

Product sales
Total Revenues

37,715

30,450

29,623

28,056

19,759

17,043

13,763

10,766

9,838

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product royalty revenues
Total Revenues

563

1,195

683

1,461

2

1,193

370

1,386

440

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenues
Total Revenues

0

-8

0

160

8

-208

23

23

1,003

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-